NO20076437L - Anti-GM-CSF antistoffer og anvendelser for disse - Google Patents

Anti-GM-CSF antistoffer og anvendelser for disse

Info

Publication number
NO20076437L
NO20076437L NO20076437A NO20076437A NO20076437L NO 20076437 L NO20076437 L NO 20076437L NO 20076437 A NO20076437 A NO 20076437A NO 20076437 A NO20076437 A NO 20076437A NO 20076437 L NO20076437 L NO 20076437L
Authority
NO
Norway
Prior art keywords
antibodies
csf
various disorders
applications
role
Prior art date
Application number
NO20076437A
Other languages
English (en)
Other versions
NO344992B1 (no
Inventor
Stefan Steidl
Elisabeth Thomassen-Wolf
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of NO20076437L publication Critical patent/NO20076437L/no
Publication of NO344992B1 publication Critical patent/NO344992B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Sammendrag Foreliggende oppfinnelse skaffer til veie rekombinant antigen-bindende regioner, antistoffer og funksjonelle fragmenter av disse som er spesifikke for GM-CSF, som spiller en integrert rolle i forskjellige forstyrrelser og forhold. Disse antistoffene kan således bli anvendt for å behandle, for eksempel inflammatoriske sykdommer slik som reumatoid artritt. Antistoffer fra oppfinnelsen kan også bli anvendt innen det diagnostiske feltet, så vel som for videre undersøkelser av rollen til GM-CSF i utvikling av for skjellige forstyrrelser. Oppfinnelsen skaffer også til veie nukleinsyre sekvenser som koder for foregående antistoffer, vektorer som inneholder det samme, farmasøytiske sammensetninger og kits (sett) med instruksjoner for bruk.
NO20076437A 2005-05-18 2007-12-13 Anti-GM-CSF antistoffer og anvendelser for disse NO344992B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68200905P 2005-05-18 2005-05-18
PCT/EP2006/004696 WO2006122797A2 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor

Publications (2)

Publication Number Publication Date
NO20076437L true NO20076437L (no) 2007-12-13
NO344992B1 NO344992B1 (no) 2020-08-17

Family

ID=37114333

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076437A NO344992B1 (no) 2005-05-18 2007-12-13 Anti-GM-CSF antistoffer og anvendelser for disse

Country Status (26)

Country Link
US (5) US7867495B2 (no)
EP (4) EP1888643B1 (no)
JP (2) JP5295759B2 (no)
KR (1) KR101308087B1 (no)
CN (2) CN101218255B (no)
AR (1) AR053608A1 (no)
AU (1) AU2006249062B2 (no)
BR (1) BRPI0610796B8 (no)
CA (1) CA2608498C (no)
DK (2) DK1888643T3 (no)
ES (2) ES2918209T3 (no)
HK (1) HK1114620A1 (no)
HR (2) HRP20220755T3 (no)
HU (1) HUE058876T2 (no)
IL (1) IL187375A (no)
LT (1) LT3620171T (no)
ME (1) ME02059B (no)
NO (1) NO344992B1 (no)
NZ (1) NZ564027A (no)
PL (2) PL1888643T3 (no)
PT (2) PT1888643E (no)
RS (2) RS53743B1 (no)
RU (1) RU2447085C2 (no)
SI (2) SI1888643T1 (no)
TW (1) TWI477512B (no)
WO (1) WO2006122797A2 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1874819E (pt) 2005-04-18 2015-09-17 Amgen Res Munich Gmbh Neutralizadores de anticorpos do fator humano de estimulação de colónias de macrófagos e granulócitos
KR101308087B1 (ko) 2005-05-18 2013-10-16 모르포시스 아게 항-ｇｍ-ｃｓｆ 항체 및 이의 용도
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
PL1981909T3 (pl) * 2006-02-08 2017-08-31 Morphotek, Inc. Antygenowe peptydy GM-CSF oraz przeciwciała wobec GM-CSF
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
BRPI0719109A2 (pt) 2006-11-21 2013-12-10 Kalobios Pharmaceuticals Inc Métodos para tratar doenças inflamatórias crônicas usando um antagonista de gm-csf
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AU2008323608A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
CA2705539A1 (en) * 2007-11-13 2009-05-22 Evec Inc. Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
CN104151429B (zh) 2007-11-26 2018-07-10 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
KR101852915B1 (ko) * 2008-04-28 2018-04-27 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
WO2009142738A2 (en) * 2008-05-21 2009-11-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
MX2011000041A (es) * 2008-07-02 2011-05-23 Emergent Product Dev Seattle Proteinas antagonistas del factor-alfa de necrosis tumoral (tnf-alfa), de union a multiples objetivos.
CN106397591A (zh) * 2008-12-22 2017-02-15 墨尔本大学 骨关节炎治疗
CN108014335A (zh) * 2008-12-22 2018-05-11 墨尔本大学 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途
SG175305A1 (en) * 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
KR20140064943A (ko) * 2009-05-05 2014-05-28 모르포시스 아게 다발성 경화증의 치료
KR20140061379A (ko) * 2011-07-06 2014-05-21 모르포시스 아게 항­ｃｄ20 및 항­ｇｍ­ｃｓｆ 항체의 치료 조합물 및 이의 용도
US9901079B2 (en) * 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
EP2843051B1 (en) 2012-04-23 2018-06-06 GeneFrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
JP6437913B2 (ja) * 2012-08-17 2018-12-12 モルフォシス・アーゲー 複合体特異的抗体及び抗体断片並びにその使用
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
SG11201501595YA (en) * 2012-09-20 2015-05-28 Morphosys Ag Treatment for rheumatoid arthritis
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN108424453B (zh) 2012-11-09 2021-08-06 基因先端领域株式会社 用于治疗癌症的抗adam28抗体
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
ES2860480T3 (es) 2013-08-30 2021-10-05 Takeda Gmbh Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
US11173208B2 (en) 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
JP6490419B2 (ja) * 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
US10329358B2 (en) 2015-03-06 2019-06-25 Genefrontier Corporation Anti-human membrane-type ADAM28 antibody
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
PT3328887T (pt) * 2016-09-19 2021-10-19 I Mab Biopharma Hangzhou Co Ltd Anticorpos anti-gm-csf e suas utilizações
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10870703B2 (en) 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
CN113453759A (zh) 2018-11-09 2021-09-28 基尼克萨制药有限公司 治疗巨细胞动脉炎
EP3908303A4 (en) * 2019-01-07 2023-05-03 Hunan Siweikang Therapeutics Co. Ltd MODIFIED IMMUNE CELLS CO-EXPRESSING A CHIMERIC ANTIGEN RECEPTOR AND AN IL-6 ANTAGONIST TO REDUCE TOXICITY, AND USES THEREOF IN ADOPTIVE CELL THERAPY
EP3976080A1 (en) 2019-06-03 2022-04-06 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
EP1144607B1 (en) 1999-07-20 2008-12-17 MorphoSys AG Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
EP1572971B1 (en) 2002-11-15 2009-09-30 Morphotek Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
DE602004021773D1 (de) 2004-05-05 2009-08-13 Micromet Ag Herstellung eines einkettigen fv Antikörperfragments
KR101308087B1 (ko) * 2005-05-18 2013-10-16 모르포시스 아게 항-ｇｍ-ｃｓｆ 항체 및 이의 용도

Also Published As

Publication number Publication date
TW200716674A (en) 2007-05-01
LT3620171T (lt) 2022-06-10
BRPI0610796A2 (pt) 2010-11-09
NZ564027A (en) 2011-06-30
PL1888643T3 (pl) 2015-04-30
EP2468773A3 (en) 2012-09-19
CN101218255B (zh) 2013-01-09
IL187375A0 (en) 2008-02-09
HK1114620A1 (en) 2008-11-07
JP2013116912A (ja) 2013-06-13
WO2006122797B1 (en) 2007-04-19
CN103087190B (zh) 2016-08-03
CA2608498A1 (en) 2006-11-23
KR101308087B1 (ko) 2013-10-16
US10377820B2 (en) 2019-08-13
JP2008545632A (ja) 2008-12-18
IL187375A (en) 2012-06-28
JP5769744B2 (ja) 2015-08-26
PL3620171T3 (pl) 2022-08-08
EP1888643A2 (en) 2008-02-20
PT1888643E (pt) 2015-01-14
AU2006249062B2 (en) 2012-12-20
PT3620171T (pt) 2022-06-30
EP2468773A2 (en) 2012-06-27
US20200024340A1 (en) 2020-01-23
EP3620171B1 (en) 2022-04-20
HUE058876T2 (hu) 2022-09-28
RS53743B1 (en) 2015-06-30
SI3620171T1 (sl) 2022-09-30
US20090053213A1 (en) 2009-02-26
WO2006122797A3 (en) 2007-02-15
US7867495B2 (en) 2011-01-11
EP1888643B1 (en) 2014-10-29
HRP20150023T1 (hr) 2015-02-27
AU2006249062A1 (en) 2006-11-23
US20170218061A1 (en) 2017-08-03
RU2007147870A (ru) 2009-06-27
US11028165B2 (en) 2021-06-08
RU2447085C2 (ru) 2012-04-10
BRPI0610796B1 (pt) 2020-01-21
BRPI0610796B8 (pt) 2021-05-25
CA2608498C (en) 2017-04-04
DK1888643T3 (en) 2015-01-05
ES2527428T3 (es) 2015-01-23
CN101218255A (zh) 2008-07-09
ES2918209T3 (es) 2022-07-14
NO344992B1 (no) 2020-08-17
US20110045000A1 (en) 2011-02-24
WO2006122797A2 (en) 2006-11-23
DK3620171T3 (da) 2022-06-07
CN103087190A (zh) 2013-05-08
US9751939B2 (en) 2017-09-05
EP3150221A1 (en) 2017-04-05
SI1888643T1 (sl) 2015-03-31
ME02059B (me) 2015-05-20
AR053608A1 (es) 2007-05-09
TWI477512B (zh) 2015-03-21
HRP20220755T3 (hr) 2022-09-02
JP5295759B2 (ja) 2013-09-18
EP3620171A1 (en) 2020-03-11
RS63382B1 (sr) 2022-08-31
KR20080015008A (ko) 2008-02-15
US20210347879A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
NO20076437L (no) Anti-GM-CSF antistoffer og anvendelser for disse
NO20063986L (no) Anti-CD-38-humane antistoffer og anvendelse derav
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
DK1937721T3 (da) Anti-IL-23 antistoffer
EA200870050A1 (ru) Анти-il-17-антитела
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
UA100377C2 (en) Antibodies against il-25
TN2010000234A1 (en) Anti-mesothelin antibodies and uses therefor
EA201100516A1 (ru) Fgf21 мутанты и их применение
CL2007001840A1 (es) Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201000424A1 (ru) Антитела к il-23
NO20083690L (no) Hydantoin baserte kinase-inhibitorer
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20073981L (no) Criptobindende molekyler
NO20080246L (no) Anti-IGF1R-antistofformuleringer
EA201690946A1 (ru) Мутанты fgf21 и их применение
MX2009002816A (es) Proteinas de fusion de albumina.
EA200970113A1 (ru) Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н
WO2009130296A3 (en) Anti-alk1 antibodies and uses thereof
UA99714C2 (ru) Моноклональное антитело, которое специфически связывается с light
CY1115920T1 (el) Αντι-gm-csf αντισωματα και χρησεις αυτων
CY1116202T1 (el) Ενωσεις που περιεχουν διφθοριο ως αναστολεις των κυστεϊνικων πρωτεασεων
CY1116001T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MORPHOSYS AG, DE